2,378 Matching Annotations
  1. Jan 2021
    1. ReconfigBehSci. (2020, November 9). RT @peterbachmd: Relevant today: Ever sharp @nataliexdean on Vaccine Effectiveness vs Efficacy from many moons ago (i.e. About a month). Sh… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1325889181097267200

  2. Dec 2020
    1. mRNA-1273 vaccine candidate, manufactured by Moderna, encodes the S-2P antigen, consisting of the SARS-CoV-2 glycoprotein with a transmembrane anchor and an intact S1–S2 cleavage site. S-2P is stabilized in its prefusion conformation by two consecutive proline substitutions at amino acid positions 986 and 987, at the top of the central helix in the S2 subunit
    1. We report the preclinical development of BNT162b2, a lipid-nanoparticle (LNP) formulated N1-methyl-pseudouridine (m1Ψ) nucleoside-modified mRNA (modRNA) vaccine candidate that encodes P2 S with a native furin cleavage site resulting in the S1 and S2 cleavage fragments
    2. To generate the template for RNA synthesis, a DNA fragment encoding the SARS-CoV-2 P2 279 S protein (based on GenBank: MN908947), including the amino acid exchanges K986P and 280 V987P, was cloned into a starting plasmid vector with backbone sequence elements for 281 improved RNA stability and translational efficiency19,34

      BNT162b2

    1. The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.

      Is this expectation higher than for other coronavirus vaccines? MHRA: Medicines & Healthcare products Regulatory Agency

    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

    1. In a webinar hosted by MIT Sloan School of Management professor Andrew Lo on April 1, Bancel said that Moderna is already manufacturing mRNA for vaccines in its potential Phase II study, which could begin enrolling hundreds of people this spring, as well as its potential Phase III study, which could enroll thousands of people as early as late summer or early fall. In a US Securities and Exchange Commission filing the week before, Bancel also indicated that Moderna may request special permission to give people like doctors and nurses access to its vaccine this fall, before a formal approval. It’s an audacious plan for a company—and technology—that has yet to put a drug on the market.
  3. Nov 2020
  4. Oct 2020
  5. Sep 2020
  6. Aug 2020
    1. Felipe, L. S., Vercruysse, T., Sharma, S., Ma, J., Lemmens, V., Looveren, D. van, Javarappa, M. P. A., Boudewijns, R., Malengier-Devlies, B., Kaptein, S. F., Liesenborghs, L., Keyzer, C. D., Bervoets, L., Rasulova, M., Seldeslachts, L., Jansen, S., Yakass, M. B., Quaye, O., Li, L.-H., … Dallmeier, K. (2020). A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate. BioRxiv, 2020.07.08.193045. https://doi.org/10.1101/2020.07.08.193045

    1. Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6

    1. Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 1–8. https://doi.org/10.1038/s41586-020-2622-0

    1. Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., Navarro, M. J., Miranda, M. C., Pettie, D., Ravichandran, R., Kraft, J. C., Ogohara, C., Palser, A., Chalk, S., Lee, E.-C., … King, N. P. (2020). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. BioRxiv, 2020.08.11.247395. https://doi.org/10.1101/2020.08.11.247395

    1. Sun, W., McCroskery, S., Liu, W.-C., Leist, S. R., Liu, Y., Albrecht, R. A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., Dinnon, K. H., Innis, B. L., García-Sastre, A., Krammer, F., Baric, R. S., & Palese, P. (2020). A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. BioRxiv, 2020.07.30.229120. https://doi.org/10.1101/2020.07.30.229120

    1. Bangaru, S., Ozorowski, G., Turner, H. L., Antanasijevic, A., Huang, D., Wang, X., Torres, J. L., Diedrich, J. K., Tian, J.-H., Portnoff, A. D., Patel, N., Massare, M. J., Yates, J. R., Nemazee, D., Paulson, J. C., Glenn, G., Smith, G., & Ward, A. B. (2020). Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. BioRxiv, 2020.08.06.234674. https://doi.org/10.1101/2020.08.06.234674

  7. Jul 2020
    1. Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. P., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fonter-Garfias, C., Shi, P.-Y., Tuereci, O., Tompkins, K. R., Walsh, E. E., … Jansen, K. U. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRxiv, 2020.06.30.20142570. https://doi.org/10.1101/2020.06.30.20142570

    1. Corbett, K. S., Edwards, D., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. BioRxiv, 2020.06.11.145920. https://doi.org/10.1101/2020.06.11.145920

  8. Jun 2020
    1. Starr, T. N., Greaney, A. J., Hilton, S. K., Crawford, K. H., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., Veesler, D., & Bloom, J. D. (2020). Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding [Preprint]. Microbiology. https://doi.org/10.1101/2020.06.17.157982

    1. . According to published reports, the vaccine being developed uses a replication-deficient adenovirus (a harmless virus) to deliver a SARS-CoV-2 protein to induce a protective immune response. Coded as ChAdOx1, the same vaccine has been used against several other pathogens, including one for the Mers virus.

      Still nothing in sight!

    2. Kang cited how the BCG vaccine underwent as many as 200 sub-cultures before it was considered attenuated (weakened) enough for human use. Another leading virologist tells ET Prime that Moderna is in an uncharted territory and no vaccine using that technology has reached the licensing stage.

      Requires significant attenuation before you actually see results.

    3. Known as messenger RNA, Moderna’s vaccine essentially aims to induce an immune response by sending instruction signals for a spike protein located on the surface of the virus. These immune cells are then expected to develop antibodies against the virus whenever a person contracts the coronavirus. Although promising, this pathway has not been successful or used to develop vaccines before.

      Novel form of vaccine but not entirely worth it.

    4. Moderna had earlier announced that it would start its pivotal phase III studies in July, to be followed by a biologic-licence application (BLA) with the USFDA. While apprehensions have been raised over that timeline, senior researchers like Fauci who had backed Moderna’s vaccine have not made any observations on the quality of data shared.

      Very bad quality of data

    5. He passionately explains how his team developed a reverse-genetics system against a poultry virus called avian paramyxovirus. In simple terms, this is a method of recovering a virus, manipulating its genome, and using it as a vector to induce an immune response.
    6. A few days ago, the US launched a public-private partnership under Operation Warp Speed that hand-picked five companies that can develop and make vaccines, diagnostics, and therapeutics on an accelerated basis.
    7. Hundreds of chemistry-based and biological drugs – new and existing – are being tested everyday across continents to rein in the coronavirus, but so far only one has shown partial activity.
    1. Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., … Nussenzweig, M. C. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals [Preprint]. Immunology. https://doi.org/10.1101/2020.05.13.092619

  9. May 2020
    1. Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., Marrama, D., de Silva, A. M., Frazier, A., Carlin, A., Greenbaum, J. A., Peters, B., Krammer, F., Smith, D. M., Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, S0092867420306103. https://doi.org/10.1016/j.cell.2020.05.015

  10. Apr 2020
    1. Adams, E. R., Anand, R., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E., Bell, J., Berry, T., Bibi, S., Carroll, M., Chinnakannan, S., Clutterbuck, E., Cornall, R. J., Crook, D. W., Silva, T. D., Dejnirattisai, W., Dingle, K. E., Dold, C., Eyre, D. W., … Sanchez, V. (2020). Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. MedRxiv, 2020.04.15.20066407. https://doi.org/10.1101/2020.04.15.20066407

    1. Newton, P. N., Bond, K. C., Adeyeye, M., Antignac, M., Ashenef, A., Awab, G. R., Babar, Z.-U.-D., Bannenberg, W. J., Bond, K. C., Bower, J., Breman, J., Brock, A., Caillet, C., Coyne, P., Day, N., Deats, M., Douidy, K., Doyle, K., Dujardin, C., … Zaman, M. (2020). COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. The Lancet Global Health, S2214109X20301364. https://doi.org/10.1016/S2214-109X(20)30136-4

  11. Mar 2017
    1. Can the flu vaccine give you the flu? As you might have guessed already given our description of how flu vaccines are made, the answer is unequivocally no- you’re not going to get the flu from the flu vaccine
  12. Aug 2016
  13. Jan 2015
    1. How interesting! It's the same in my family. Certain members will take as gospel, the opinions of the people they deem to have credibility, but eschew - and even satirically cauterize - the wisdom and factual evidence of people with the authority and knowledge.

      It's most frustrating. As for me, I try not to read comments. They just make me so angry!